Log in

NYSE:RDY - Dr.Reddy's Laboratories Stock Price, Forecast & News

$39.55
-0.78 (-1.93 %)
(As of 04/2/2020 02:41 AM ET)
Today's Range
$38.71
Now: $39.55
$40.44
50-Day Range
$34.75
MA: $41.18
$45.85
52-Week Range
$33.33
Now: $39.55
$46.19
Volume215,400 shs
Average Volume215,387 shs
Market Capitalization$6.55 billion
P/E Ratio28.05
Dividend Yield0.64%
Beta0.23
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. It also provides a portfolio of in-licensed dermatology products. As of March 31, 2018, this segment had 13 active products development programs pipeline that are in various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, pain management, oncology, dermatology, urology, and nephrology. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology; and collaboration agreement with Merck Serono to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. Dr. Reddy's Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.
Read More
Dr.Reddy

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone91-40-4900-2900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.23 billion
Cash Flow$2.65 per share
Book Value$12.21 per share

Profitability

Net Income$272 million

Miscellaneous

Employees21,966
Market Cap$6.55 billion
Next Earnings Date5/15/2020 (Estimated)
OptionableOptionable

Receive RDY News and Ratings via Email

Sign-up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter.


Dr.Reddy's Laboratories (NYSE:RDY) Frequently Asked Questions

How has Dr.Reddy's Laboratories' stock been impacted by COVID-19 (Coronavirus)?

Dr.Reddy's Laboratories' stock was trading at $40.17 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RDY stock has decreased by 1.5% and is now trading at $39.55. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Dr.Reddy's Laboratories?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dr.Reddy's Laboratories in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Dr.Reddy's Laboratories.

When is Dr.Reddy's Laboratories' next earnings date?

Dr.Reddy's Laboratories is scheduled to release its next quarterly earnings announcement on Friday, May 15th 2020. View our earnings forecast for Dr.Reddy's Laboratories.

How were Dr.Reddy's Laboratories' earnings last quarter?

Dr.Reddy's Laboratories Ltd (NYSE:RDY) released its quarterly earnings results on Monday, January, 27th. The company reported $0.40 earnings per share (EPS) for the quarter. The firm had revenue of $614 million for the quarter. Dr.Reddy's Laboratories had a return on equity of 18.08% and a net margin of 9.62%. View Dr.Reddy's Laboratories' earnings history.

What price target have analysts set for RDY?

7 brokerages have issued twelve-month target prices for Dr.Reddy's Laboratories' stock. Their forecasts range from $39.00 to $39.00. On average, they anticipate Dr.Reddy's Laboratories' share price to reach $39.00 in the next year. This suggests that the stock has a possible downside of 1.4%. View analysts' price targets for Dr.Reddy's Laboratories.

Has Dr.Reddy's Laboratories been receiving favorable news coverage?

Media stories about RDY stock have trended very negative on Thursday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Dr.Reddy's Laboratories earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutDr.Reddy's Laboratories.

Who are some of Dr.Reddy's Laboratories' key competitors?

What other stocks do shareholders of Dr.Reddy's Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dr.Reddy's Laboratories investors own include Siemens (SIEGY), Tata Motors (TTM), Infosys (INFY), Vedanta (VEDL), HDFC Bank (HDB), GlaxoSmithKline (GSK), Merck & Co., Inc. (MRK), AstraZeneca (AZN), ICICI Bank (IBN) and Gilead Sciences (GILD).

Who are Dr.Reddy's Laboratories' key executives?

Dr.Reddy's Laboratories' management team includes the following people:
  • Mr. Gunupati Venkateswara Prasad, Co-Chairman, MD, CEO & Member of Management Council (Age 59)
  • Mr. Kallam Satish Reddy, Chairman & Member of the Management Council (Age 52)
  • Mr. Saumen Chakraborty, Pres, CFO, Global Head of IT & Bus. Process Excellence and Member of the Mgmt Council (Age 58)
  • Mr. M. V. Ramana, CEO & Head of Branded Markets - India & Emerging Countries and Member of Management Council (Age 50)
  • Mr. Ganadhish Kamat, Exec. VP, Global Head of Quality & Member of Management Council (Age 56)

What is Dr.Reddy's Laboratories' stock symbol?

Dr.Reddy's Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "RDY."

How do I buy shares of Dr.Reddy's Laboratories?

Shares of RDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Dr.Reddy's Laboratories' stock price today?

One share of RDY stock can currently be purchased for approximately $39.55.

How big of a company is Dr.Reddy's Laboratories?

Dr.Reddy's Laboratories has a market capitalization of $6.55 billion and generates $2.23 billion in revenue each year. The company earns $272 million in net income (profit) each year or $1.64 on an earnings per share basis. Dr.Reddy's Laboratories employs 21,966 workers across the globe. View additional information about Dr.Reddy's Laboratories.

What is Dr.Reddy's Laboratories' official website?

The official website for Dr.Reddy's Laboratories is http://www.drreddys.com/.

How can I contact Dr.Reddy's Laboratories?

Dr.Reddy's Laboratories' mailing address is 8-2-337 ROAD NO.3 BANJARA HILLS, HYDERABAD K7, 500-034. The company can be reached via phone at 91-40-4900-2900 or via email at [email protected]


MarketBeat Community Rating for Dr.Reddy's Laboratories (NYSE RDY)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  280 (Vote Outperform)
Underperform Votes:  397 (Vote Underperform)
Total Votes:  677
MarketBeat's community ratings are surveys of what our community members think about Dr.Reddy's Laboratories and other stocks. Vote "Outperform" if you believe RDY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/2/2020 by MarketBeat.com Staff

Featured Article: What is a Buy-Side Analyst?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel